ReviewPregnancy (Hoboken, N.J.)2025
Low-dose aspirin in unexplained recurrent pregnancy loss: A systematic review and meta-analysis.
Review in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recurrent pregnancy loss (RPL), defined as two or more consecutive pregnancy losses before 24 weeks of gestation, affects approximately 1%-2% of couples of reproductive ages. Despite comprehensive diagnostic work-up, up to 40%-50% of cases remain unexplained (uRPL). Low-dose aspirin (LDA) (50, 75, or 80 mg) administration during pregnancy has been proposed as a potential treatment to improve obstetric outcomes in women with uRPL. However, its efficacy in preventing pregnancy loss remains unclear. The aim of this systematic review and meta-analysis was to evaluate the efficacy of LDA administration on the pregnancy outcomes of women with uRPL. Methods: We systematically searched for relevant studies in PubMed, Scopus, EMBASE, Google Scholar, and the Cochrane Library without language restriction from inception until April 2025. Randomized controlled trials (RCTs) that summarize the evidence regarding the effect of LDA on obstetric outcomes in women with uRPL were included. The counted data were analyzed using relative risk (RR) as the effect-size statistic, and each effect size was assigned its 95% confidence interval (CI). This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary outcome was the live birth rate (LBR), and secondary outcomes included preeclampsia and fetal growth restriction rates. Results: Three RCTs were included, involving a total of 656 participants. No significant improvements were observed in terms of LBR in uRPL treated with daily administration of a 50-80 mg aspirin compared to untreated uRPL women (RR = 0.97, 95% CI, 0.90-1.04, Conclusions: Our findings suggested that a 50-80 mg daily dose of aspirin does not improve the LBR of women with uRPL. Further studies, specifically RCTs using a 150 mg dose of aspirin in uRPL, are needed to clarify the efficacy of acetylsalicylic acid in preventing placental insufficiency-related pregnancy loss. PROSPERO Registration: CRD420251024932.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.